Loading
Cancer Related Molecular Mechanisms Research · Journal article
Research Journal of Biotechnology · July 31, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that surveys functional genomics strategies—including high-throughput sequencing, CRISPR gene editing, and computational approaches—for studying noncoding RNA roles in cancer, heart, neurodegenerative, and autoimmune diseases. It is a methodological synthesis that identifies gaps in functional validation and clinical translation rather than a test of a specific intervention or biomarker.
Journal article. Conceptual; review addresses noncoding RNA roles across multiple human disease categories (cancer, heart disease, neurodegeneration, autoimmunity) without a specific study population..
Noncoding RNAs (microRNAs, long noncoding RNAs, circRNAs) are implicated in pathogenesis of cancer, heart, neurodegenerative and autoimmune diseases. Functional genomics enables large-scale analysis of ncRNA expression, interactions, regulatory networks, and identification of disease-specific biomarkers. Integration of computational biology, machine learning and systems biology enhances interpretation of ncRNA roles in disease networks.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review outlines the current landscape of functional genomics tools for ncRNA discovery but does not provide evidence that applying these methods to a specific disease or patient population will improve diagnosis, prognosis, or treatment. Clinicians should treat this as an overview of emerging methodologies rather than a guide to clinical implementation.
This is a narrative review synthesizing functional genomics approaches to noncoding RNA biology; it raises mechanistic questions and describes methodological frameworks rather than testing hypotheses with empirical data or clinical outcomes.
This review outlines the current landscape of functional genomics tools for ncRNA discovery but does not provide evidence that applying these methods to a specific disease or patient population will improve diagnosis, prognosis, or treatment. Clinicians should treat this as an overview of emerging methodologies rather than a guide to clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Noncoding RNA (NCRNA), once considered genomic "dark matter," has emerged as an essential regulator of gene expression and is rapidly implicated in the pathogenesis of various human diseases. Functional genomics has brought a revolution to our understanding of these RNA molecules, including microRNAs, long noncoding RNAs and circular RNAs (circRNAs), by enabling their expression, interaction and large-scale analysis of the regulatory network. With the advancement of high-throughput sequencing, CRISPR-based gene editing and transcription, functional genomics offers a wealth of insights into how ncRNAs contribute to the onset, progression and tissue specificity of diseases. These approaches facilitate the identification of NCRNA biomarkers, highlight their epigenetic and transcriptional control mechanisms and illustrate their interactions with DNA, RNA and proteins. In cancer, heart, neurodegenerative and autoimmune diseases, converted NCRNA profiles are now recognized as a significant reorganization of signaling pathways and cellular homeostasis. Additionally, a functional genomics background improves transcriptional noise, enhancing AIDS, clinical accuracy and medical goal discovery in separating disease-specific NCRNAs. The integration of computational biology, machine learning and systems biology further enhances our ability to interpret NCRNA tasks and predict their roles in the disease network. Despite significant progress, challenges remain in functionally validating NCRNAs and translating genomic data into clinical applications. This study discusses the latest functional genomics strategies used to examine NCRNAS and highlights their transformative ability in accurate therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.